We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Zeyad Schwen

Zeyad R. Schwen MD

Fellow, Advanced Robotics and Laparoscopy, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio

Dr. Schwen is a Fellow at the Glickman Urological and Kidney Institute at the Cleveland Clinic in Ohio. Prior to joining the Cleveland Clinic, Dr. Schwen completed his urologic residency at the Brady Urological Institute at Johns Hopkins Hospital in Baltimore. During his time at Johns Hopkins, Dr. Schwen published extensively on topics within urologic oncology with a primary focus on active surveillance for prostate cancer and renal cell carcinoma as well as the surgical management of testicular and prostate cancer. For his research efforts, Dr. Schwen was the recipient of two grants evaluating the genomic landscape of early-stage renal cell carcinoma and surgical outcomes after radical prostatectomy.

Dr. Schwen received his medical degree from the University of Pittsburgh School of Medicine and holds a B.S. in biomedical engineering from Case Western Reserve University. His engineering background has inspired a passion for clinical research with medical devices and robotic technology including novel technologies for the surgical management and diagnosis of prostate cancer and urothelial cancer.

His current research interests include artificial intelligence, prostate cancer active surveillance, and surgical robotics and ergonomics.


No relevant conflicts of interest or financial disclosures.